ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

ClinicalTrials.gov ID: NCT04817618

Public ClinicalTrials.gov record NCT04817618. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 9:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Complement 3 Glomerulopathy.

Study identification

NCT ID
NCT04817618
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
98 participants

Conditions and interventions

Conditions

Interventions

  • Placebo Drug
  • iptacopan Drug

Drug

Eligibility (public fields only)

Age range
12 Years to 60 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 27, 2021
Primary completion
Jan 28, 2027
Completion
Jan 28, 2027
Last update posted
Apr 28, 2026

2021 – 2027

United States locations

U.S. sites
13
U.S. states
11
U.S. cities
12
Facility City State ZIP Site status
Childrens Hospital Colorado Aurora Colorado 80045 Recruiting
Nicklaus Childrens Hospital Miami Florida 33155 Recruiting
Georgia Nephrology Research Inst Lawrenceville Georgia 30046 Active, not recruiting
IN University School of Med Indianapolis Indiana 46202-5111 Withdrawn
University of Iowa Health Care Iowa City Iowa 52242-1091 Recruiting
University of Iowa Health Care Iowa City Iowa 52242 Recruiting
Johns Hopkins Hospital Baltimore Maryland 21287 Withdrawn
Brigham and Womens Hosp Harvard Med School Boston Massachusetts 02115 Withdrawn
Hackensack Uni Medical Center Hackensack New Jersey 07601 Withdrawn
Albany Medical Center Albany New York 12208 Withdrawn
Col Uni Med Center New York Presby New York New York 10032 Completed
Baylor Scott and White Research Temple Texas 76502 Withdrawn
University of Wisconsin Madison Wisconsin 53792 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 72 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04817618, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 28, 2026 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04817618 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →